Value of <scp>MRI</scp> Outcomes for Preventive and Early‐Stage Trials in Spinocerebellar Ataxias 1 and 3

The estimated sample sizes to detect a 50% reduction in progression with 80% power using the pons volume as primary outcome measure indicate the feasibility of preventive trials (n = 73 per arm in a 1-year trial) in common SCAs and predict a 6-fold reduction in required sample sizes relative to SARA in early interventional trials. These findings support the use of MRI endpoints in early-stage SCA trials.

Authors

Institutions

Publication Details

Journal
Annals of Clinical and Translational Neurology
Published
2026-02-10
DOI
https://doi.org/10.1002/acn3.70325
Primary Topic
Genetic Neurodegenerative Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Value of MRI Outcomes for Preventive and Early‐Stage Trials in Spinocerebellar Ataxias 1 and 3

Readisca Investigators, R. Valabrègue, Young Woo Park, James M. Joers et al.
Annals of Clinical and Translational Neurology
Genetic Neurodegenerative Diseases
article

Value of MRI Outcomes for Preventive and Early‐Stage Trials in Spinocerebellar Ataxias 1 and 3

Readisca Investigators, R. Valabrègue, Young Woo Park, James M. Joers, Philipp Ehses, Emilien Petit, Jeremy D. Schmahmann, J. R. Rezende Thiago, Guita Banan, Thomas H. Mareci, Christophe Lenglet, Michal Považan, İpek Özdemir, P BARKER, S. H. Subramony, SUB SUBRAMONY, Eva Ratai, Gülin Öz, A. Durr, Jennifer Faber, Sophie Tezenas du Montcel, H. Moore Arnold, Thomas Klockgether, Jonathan M. DuBois, Tetsuo Ashizawa, Henry Paulson, Chiadi U. Onyike
article en

Abstract

The estimated sample sizes to detect a 50% reduction in progression with 80% power using the pons volume as primary outcome measure indicate the feasibility of preventive trials (n = 73 per arm in a 1-year trial) in common SCAs and predict a 6-fold reduction in required sample sizes relative to SARA in early interventional trials. These findings support the use of MRI endpoints in early-stage SCA trials.

Annals of Clinical and Translational Neurology
Henry M. Jackson Foundation (US), Centre National de la Recherche Scientifique (FR), Biogen (United States) (US), Johns Hopkins University (US), Uniformed Services University of the Health Sciences (US), Inserm (FR), Universidade Estadual de Campinas (UNICAMP) (BR), Cornell University (US), University of Michigan (US), University Hospital Bonn (DE), Johns Hopkins Medicine (US), German Center for Neurodegenerative Diseases (DE), University of Florida (US), Sorbonne Université (FR), Assistance Publique – Hôpitaux de Paris (FR), Center for Neuro-Oncology (US), Methodist Hospital (US), Athinoula A. Martinos Center for Biomedical Imaging (US), Institut de Psychiatrie et Neurosciences de Paris (FR), Resonance Research (United States) (US)
Openalex Percentile: Top 63%
Genetic Neurodegenerative Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.